Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Explore this paper's citation graph
Summary
These 2-year follow-up data from ZUMA-1 suggest that axicabtagene ciloleucel can induce durable responses and the proportion of patients achieving an objective response for phase 2, and key secondary endpoints were overall survival, progression-free survival, and duration of response.
- Type
- article
- Published
- 2018-12-02
- Cited by
- 1,799
- References
- 33
- Access
- Open access
- OpenAlex
- https://openalex.org/W2903225254
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:54560386
Keywords
Medicine, Refractory (planetary science), Oncology, Lymphoma, Internal medicine
References
- Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
- Long-Term Survival And Late Relapse In 2-Year Survivors Of Autologous Hematopoietic Cell Transplantation For Hodgkin And Non-Hodgkin Lymphoma
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.
- Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study
- Current concepts in the diagnosis and management of cytokine release syndrome.
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- Revised response criteria for malignant lymphoma.
- Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry.
- Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
- Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
- Toxicities of chimeric antigen receptor T cells: recognition and management.
- Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
- Chimeric Antigen Receptor T-cell Therapies for Lymphoma
- A Possible Cure for Refractory DLBCL: CARs Are Headed in the Right Direction.
- Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL
- Long-Term Outcomes Among Two-Year Survivors of Autologous Hematopoietic Cell Transplant for Hodgkin and Diffuse Large B-Cell Lymphoma
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Cited by
- CD19-directed CAR T cells gain traction.
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
- PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.
- Anti-CD19 CAR T cell therapy for lymphoma — off to the races!
- Early and late hematologic toxicity following CD19 CAR-T cells
- Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma
- Chimeric Antigen Receptor–Engineered T Cell Therapy in Lymphoma
- In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
- Wishing on a CAR: Understanding the Scope of Intrinsic T-cell Deficits in Patients with Cancer.
- CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm
- Newer biological agents: CAR T cells, PARP inhibitors, and ALK inhibitors
- CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
- CAR-T efficacy: is conditioning the key?
- Novel approaches to promote CAR T-cell function in solid tumors
- Hypoxia Selectively Impairs CAR-T Cells In Vitro
- Health and healthcare in the Fourth Industrial Revolution: Global Future Council on the Future of Health and Healthcare 2016-2018
- Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
- Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity?
- Modelling uncertainty in survival and cost-effectiveness is vital in the era of gene therapies: the case of axicabtagene ciloleucel
Related papers
- DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION
- Genentech taps Affimed’s antibodies
- KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria
- Cardiac retransplantation in children.
- Avaliacao hemodinamica sequencial em transplante de coracao
- Thoracoscopic discectomy and fusion in the treatment of spinal deformities
- [Hepatic retransplant and acute Budd Chiari syndrome. Case report].